Insights into Digital Therapeutics Space and Associated Evidence Thresholds
Diana Brixner, PhD, FAMCP, of the University of Utah opens a discussion surrounding digital therapeutics.
Video Player is loading.
Recent Videos
Type 1 Diabetes: Understanding Disease Progression and Beta Cell Function
Optimizing First-Line and Sequential Therapy in Advanced NSCLC
Setting the Stage: Immunotherapy’s Impact and EMPOWER-Lung 1 Study Design
The PDE4B Pathway: Exploring Nerandomilast’s Potential in Pulmonary Fibrosis Treatment
Shared Decision-Making in AD Management
Topical Treatments in AD
Study Design and Important Baseline Characteristics
Hidden Burden of AD
Clinical Presentations of Atopic Dermatitis Across Patient Populations
Key Background Information on Atopic Dermatitis
Related Content
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021Article
In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
